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Abstract
Background: Therapeutic intervention of numerous brain-associated disorders currently remains unrealized due to serious
limitations imposed by the blood-brain-barrier (BBB). The BBB generally allows transport of small molecules, typically ,600
daltons with high octanol/water partition coefficients, but denies passage to most larger molecules. However, some
receptors present on the BBB allow passage of cognate proteins to the brain. Utilizing such receptor-ligand systems, several
investigators have developed methods for delivering proteins to the brain, a critical requirement of which involves covalent
linking of the target protein to a carrier entity. Such covalent modifications involve extensive preparative and post-
preparative chemistry that poses daunting limitations in the context of delivery to any organ. Here, we report creation of a
36-amino acid peptide transporter, which can transport a protein to the brain after routine intravenous injection of the
transporter-protein mixture. No covalent linkage of the protein with the transporter is necessary.
Approach: A peptide transporter comprising sixteen lysine residues and 20 amino acids corresponding to the LDLR-binding
domain of apolipoprotein E (ApoE) was synthesized. Transport of beta-galactosidase, IgG, IgM, and antibodies against
amyloid plques to the brain upon iv injection of the protein-transporter mixture was evaluated through staining for enzyme
activity or micro single photon emission tomography (micro-SPECT) or immunostaining. Effect of the transporter on the
integrity of the BBB was also investigated.
Principal Findings: The transporter enabled delivery to the mouse brain of functional beta-galactosidase, human IgG and
IgM, and two antibodies that labeled brain-associated amyloid beta plaques in a mouse model of Alzheimer’s disease.
Significance: The results suggest the transporter is able to transport most or all proteins to the brain without the need for
chemically linking the transporter to a protein. Thus, the approach offers an avenue for rapid clinical evaluation of
numerous candidate drugs against neurological diseases including cancer. (299 words).
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Introduction
Numerous potential drug candidates for treating brain-associ-
ated disorders involving mood, behavior, addiction, aging,
infection, cancer and neurodegenerative disease exist but thera-
peutic use of these candidate drugs currently remains unrealized
due to serious impediment imposed by the blood-brain-barrier
(BBB) [1–9]. The existence of the BBB was reported over a century
ago [10]. Transport of small molecules, typically ,600 daltons is
generally allowed by the BBB, whereas passage of larger molecules
is usually restricted. Several receptors present on the BBB are
known to allow passage of cognate protein ligands to the brain
[11–13]. Such receptor-ligand systems on the BBB have been
reportedly utilized to develop strategies for delivering target
proteins in the brain. All these approaches, however, rely on
covalent linking of a carrier peptide resembling the receptor-
binding domain of a ligand [14–16] or an antibody resembling the
ligand [17,18], to the target protein of interest. Other approaches
utilizing different peptides or proteins as transporters also require
covalent linking of a protein ‘load’ to the transporter for delivery
across the BBB [19–21].
Our previous efforts at developing avenues for increased
delivery across the BBB also depended upon covalent linking of
a protein to polyamines [22,23], or through synthetic insertions of
asparagyl/glutamyl-4-amino-butane [24]. There are considerable
technical and other challenges associated with covalent linking of a
protein to a carrier molecule in the context of delivery across the
BBB, which, conceivably, has limited translational applications of
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method abolishing the requirement for covalent modification of a
target protein to be delivered across the BBB. We reasoned that to
achieve such an objective requires a transporter that fulfills at least
two criteria: it should bind strongly to a target protein in a non-
covalent manner and it should be able to ‘piggyback’ the bound
protein across the BBB.
We have previously shown that a stretch of sixteen lysine
residues (K16) can non-covalently and strongly bind to proteins.
When the K16 stretch was linked with the signal peptide sequence
of Kaposi’s Fibroblast Growth factor, the resulting peptide
delivered the bound proteins into cells [25]. Thus, the use of
K16 would fulfill our first key requirement. To meet the second
requirement, we elected to use the low-density lipoprotein receptor
(LDLR)-binding 20-amino acid segment of apolipoprotein E
(ApoE peptide) comprising amino acids 151–170 (Swiss-Prot #
P02649). When covalently linked, this peptide can deliver
glucocerebrosidase to the brain through LDLR-mediated transcy-
tosis [16]. Subsequently, a bi-partite peptide was synthesized
comprising the ApoE peptide linked with sixteen lysine residues
(henceforth K16ApoE), which was evaluated for its potential for
non-covalent transport of proteins across the BBB. We demon-
strate successful K16ApoE-mediated non-covalent delivery of
three different proteins (beta-galactosidase, IgG and IgM) across
the BBB. To our knowledge this is the first report demonstrating
successful delivery of various proteins across the BBB that does not
involve chemically linking the proteins with a carrier entity.
Materials and Methods
Materials
Mice were maintained and used following Institutional Animal
Care and Use Committee (IACUC)-approved protocol # A3291-
01. All mice used (B6SJLF1) were female and were purchased
from the Jackson Laboratories. Bacterial beta-galactosidase was
purchased from Calbiochem (Catalog # 345788). Human IgG
and IgM were purchased from Sigma (Product Numbers I 4506
and I8260 respectively). The 4G8 monclonal antibody (cat# SIG-
39220) was purchased from Covance (Emeryville, CA). LDL
receptor antibody was from abcam (Cat # ab30532).
All peptides were synthesized at the Mayo Proteomic Core
Facility. The transporter peptide, K16ApoE, had NH2 at both
ends. The transporter peptide has the following amino acid
sequence (in single-letter code): KKKK KKKK KKKK KKKK
LRVR LASH LRKL RKRL LRDA.
Preparation of peptide-protein complex for delivery in
the brain
Required amount of the peptide and protein were mixed in a
final volume of 300 uL PBS (phosphate buffered saline), and
incubated at room temperature for 60 min. The mixture was
vortexed for a few seconds, every fifteen minutes during the
incubation period. The mixture was somewhat turbid at high
peptide and protein concentration.
The mixture was injected intravenously as a bolus into the
lumen of the femoral vein. (K16ApoE-mediated delivery of
proteins to the brain through tail-vein iv injection has not been
explored at this time). This was accomplished using a heat pulled
PE50 catheter. At the conclusion of the experiment, the mouse
was euthanized with a lethal dose of sodium pentobarbital. Each
mouse was perfused with 10 ml PBS. This perfusion was
accomplished through the standard trans cardial method [26].
The brain was removed from the skull and positioned to make an
initial coronal slice at 22.0 mm bregma. Subsequently, 25 um
coronal sections were cut on a cryostat and placed on charged
slides for staining of beta-galactosidase activity.
Staining for beta-galactosidase enzyme activity
Evaluation of beta-galactosidase enzymatic activity was accom-
plished by an initial 15 min fixation of the brain sections in 0.25%
glutaraldehyde. The slides were washed with 3 changes of PBS for
5 minutes each and then rinsed in distilled water for 5 minutes.
The brain sections were incubated in X-Gal (0.2%) working
solution, pH 7.38, for 18 hours (overnight) at 37u C in covered
containers. Following this incubation the sections were dehydrated
and coverslips were applied [21,27].
Imaging by micro single photon emission computed
tomography (microSPECT)
Micro SPECT/CT experiments were conducted on a Gamma
Medica X SPECT System (GE Healthcare). Human IgG (Sigma)
and IgM (Sigma) were labeled to a high specific activity using the
Chloramine-T method [23]. 80 ug (corresponding to ,420 uCi of
IgG and ,397 uCi of IgM) of each immunoglobulin (corresponds
to 0.53 nanomole of IgG and 0.13 nanomole of IgM, based on
molecular weights of 150 Kd and 600 Kd for IgG and IgM,
respectively) was mixed with 70-fold molar excess of K16ApoE for
1 h at room temperature and was administered in each mouse
through the use of a catheter in the femoral vein. Immediately
subsequent to the intravenous bolus injection, the mice were
imaged every hour for a total of 6 hours [28]. At the completion of
the 6 h time point, each mouse was euthanized and the systemic
blood supply was transcardially perfused with 10 ml phosphate
buffered saline, and imaged after 30 min. Results are from 6 mice
in each group.
Immunostaining of 4G8 antibody (and other antibodies)
delivered in mice brain with and without K16ApoE
Following iv injection of 4G8 IgG (Covance Research Products,
Berkeley, CA), alone or with K16ApoE, mice were overdosed with
sodium pentobarbital (200 mg/kg, ip) and perfused transcardially
with PBS followed by neutral-buffered, 10% formalin. The brains
were removed and flash frozen. Twenty-five micron sections were
cut on a cryostat and thaw-mounted on gelatine coated slides. One
set of slides from each mouse was reacted with biotinylated
secondary anti-mouse IgG antibody, ABC immunoperoxidase
(Vector M.O.M. Peroxidase Kit, PK-2200, Vector Laboratories,
Burlingame, CA), and Vector VIP peroxidase substrate (SK-4600,
Vector Laboratories, Burlingame, CA) to test for the presence of
the 4G8 IgG in the brain. Briefly, sections were washed with tris-
buffered saline, pH 7.5 (TBS). Endogenous peroxidase activity in
the sections was quenched by reacting with 0.5% H2O2 in TBS for
30 min. The sections were blocked with M.O.M blocking solution
in TBS for 60 min. The 4G8 IgG antibody was then visualized
using standard immunoperoxidase techniques with 1 h incubation
times for the biotinylated secondary antibody and ABC solutions
[29].
Two sets of adjacent sections were processed histologically to
detect amyloid deposits and plaques using two standard methods.
One set of sections underwent immunohistochemistry for amyloid
using the same 4G8 anti-APP monoclonal mouse antibody
(Covance Research Products, Berkeley, CA) in vitro to verify the
binding of the monoclonal IgG to amyloid plaques. Briefly,
sections were washed with TBS. Endogenous peroxidase activity in
the sections was quenched by reacting with 0.5% H2O2 in TBS for
30 min. The sections were blocked with M.O.M. blocking solution
in TBS for 60 min. The sections were incubated with the 4G8
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0.3% Triton-X/PBS overnight at 4uC. The primary antibody was
then visualized using an ABC immunoperoxidase kit (Vector
M.O.M. Peroxidase Kit, PK-2200) and Vector DAB (SK-4100) as
the substrate according to the instructions (Vector Laboratories,
Burlingame, CA). Another set of adjacent sections was stained with
fresh, filtered, aqueous 1% thioflavine S to stain the amyloid
plaques using a standard protocol [29]. The thioflavine S positive
amyloid plaques were visualized with epifluorescence microscopy
using filters for fluorescein isothiocyanate (excitation=488 nm;
emission=520 nm).
Results
The peptide transporter can non-covalently deliver
functional beta-galactosidase in the brain
The potential of K16ApoE for delivering a protein across the
BBB was first evaluated by intravenous (IV) injection of the
enzyme beta-galactosidase into mice with or without prior mixing
with K16ApoE (at a protein to peptide molar ratio of 1:70, based
on preliminary experiments. A wide range of protein to peptide
molar ratios up to 1:100 [higher molar ratio not tested] produced
very satisfactory results). Intense beta-galactosidase activity was
observed in the mouse brain when the enzyme-peptide mix was
injected intravenously and brain slices were prepared for enzyme
activity staining 6 h after injection,{data presented in Figure S1
demonstrate that 6 h of time is sufficient for visual evaluation of
intracerebral beta-galactosidase activity after K16ApoE-mediated
iv delivery in brain}whereas no activity was seen when the enzyme
was injected alone (Figure 1). High-magnification scan of several
regions of brain-sections stained for K16ApoE-delivered beta-
galactosidase activity show that the enzyme was delivered in nearly
every area of the brain, and appeared to have stained all cells
when compared to cells stained with hematoxylin (compare
sections A and A9, C and C9, and D and D9; Figure 1). However,
pyramidal cells in the hippocampus (compare sections B and B9)
appear to show much weaker staining for beta-galactosidase
activity compared to cells in other areas of the brain. Whether the
weak beta-galactosidase activity staining in the pyramidal cells is
due to low expression of LDLR in the hippocampus remains to be
determined. It is also possible that the peptide carrier utilizes
multiple related receptors for transcytosis, most or all of which is
expressed in most cells in the brain but cells in the hippocampus
may not express all those receptors leading to reduced uptake of a
protein ‘load’. Further, it is possible that deficient staining in the
hippocampus reflects enhanced leakage of X-gal and/or 5,59-
dibromo-4,49-dichloro-indigo (the chromophore generated upon
beta-galactosidase action on X-gal) from the pyramidal cells in the
hippocampus as compared with cells in other brain regions.
Delivery of proteins across the BBB whose functional identification
does not depend upon small molecule substrate or product might
help resolve this issue. These data, however, strongly show that the
peptide transporter can transport enzymatically functional beta-
galactosidase across the BBB and into the brain in a simple ‘mix-
and-inject’ manner.
Delivery of beta-galactosidase to the brain by the
transporter appears to be mediated by the LDLR
To assess if the delivery of beta-galactosidase in the brain via
K16ApoE is LDLR-mediated, we evaluated beta-galactosidase
staining in liver, kidney, heart, spleen and lung after intravenous
injection of the enzyme mixed with K16ApoE (Figure 2). The
Figure 1. Delivery of beta-galactosidase in mouse brain through K16ApoE and visualization of cells stained for beta-galactosidase
activity in different areas in the brain following delivery of the enzyme. Beta-galactosidase (one nanomole) was injected in mice mixed with
K16ApoE (70 nanomoles), tissue slices made six hours after injection were stained for enzyme activity (top left). Middle image, top row –an image of a
brain slice obtained after delivering beta-galactosidase without K16ApoE. Third image, top row – image of a brain slice stained with hematoxylin.
Also, high magnification (206) images from four regions of the beta-galactosidase-stained section (A,B, C and D) and hematoxylin-stained
comparable regions (A9,B 9,C 9 and D9) are shown. A,A9 - retrosplenial agranular cortex; B,B9 - CA3 field, hippocampus; C,C9 - posterior thalamic nuclear
group; D, D9 - basolateral amygdaloid nuclei, posterior. Arrows indicate some of the cells in the respective regions.
doi:10.1371/journal.pone.0028881.g001
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lung, kidney spleen and heart. The pattern of cellular uptake of
beta-galactosidase in these organs by K16ApoE is strongly
correlated with reported LDLR expression patterns in various
tissues (high in liver and brain, low in other organs) [30–32,16],
suggesting that delivery of beta-galactosidase via K16ApoE is
LDLR-mediated. Use of LDLR knockout animals should provide
important information in deciphering the mechanism underlying
K16ApoE-mediated transport of proteins across the BBB. It also
remains to be seen if K16ApoE-mediated delivery of proteins
across the BBB takes place exclusively through the LDLR; use of
LDLR-knockout animals should help resolve the issue.
Non-covalent delivery of IgG and IgM by the transporter
across the BBB
Since many potentially therapeutic proteins against brain-
associated disorders are immunoglobulins, we evaluated delivery
of normal human serum IgG and IgM with K16ApoE in mouse
brain by micro-single photon emission computed tomography
(microSPECT) imaging (Figure 3). For this, radioiodinated human
IgG and human IgM were mixed with and without K16ApoE, and
injected intravenously. Anesthetized animals were then subjected
to imaging at 1 h intervals for 6 h at which time cardiac perfusion
was done. Final imaging was performed at 30 min post-perfusion.
Several observations can be made from these experiments: First, it
appears that peak brain delivery of both IgG (Figure 3A) and IgM
(Figure 3B) occurs at 2 h after injection of the peptide-protein mix,
and then remains relatively stable up to 6 h (maximum time point
tested). Second, cardiac perfusion appears to remove most of the
radioactive protein in the vasculature, concomitantly increasing
the difference between apparent brain-uptake of the protein with
and without the transporter peptide (4.89-fold for IgG (p-
value,0.0001) and 3.94 fold for IgM (p-value 0.0009, see
Table 1). This is probably a lower estimate of the efficiency of
delivery across the BBB by the transporter, because complete
removal of the vasculature-bound labeled IgG and IgM (the
numerical value which is the denominator in the estimation) by
cardiac perfusion was not achieved. That the efficiency of delivery
is high is supported by our beta-galactosidase-based experiments
since no animal receiving beta-galactosidase injection without the
transporter showed any visually detectable intra-cerebral enzyme
activity. Finally, we note that uptake of the radiolabeled IgG and
IgM into kidney, liver/spleen and heart did not appear to depend
on whether the proteins were delivered with or without the
transporter (Figure S2). Cardiac perfusion also did not change the
accumulation of radioactivity in these organs, implying that
accumulation of proteins in these organs does not depend upon
crossing of a biological barrier harboring LDLR.
IgG delivered by the transporter across the BBB can
recognize a specific ligand in the brain
The radiolabeled immunoglobulins delivered into the brain
through K16ApoE could represent trapped molecules in the
endothelial cells at the BBB and may not reflect entry of the
delivered proteins into the brain parenchyma. Furthermore,
assessment of K16ApoE-delivered beta-galactosidase activity in
the brain was independent of binding of the enzyme with any
intra-cerebral molecular entity. For therapeutic function, most
proteins transported across the BBB must be delivered to the brain
parenchyma and be able to recognize and bind with a cognate
target molecule. To test binding specificity of the delivered protein,
we mixed an antibody against amyloid beta peptide (4G8) with
K16ApoE and injected the mixture intravenously into APP/PS1
mice (a model for Alzheimer’s disease). This antibody is known to
recognize amyloid beta plaques [33]. Results presented in Figure 4
and Figure S3 indicate that the K16-ApoE-delivered antibody
labeled the amyloid plaques in the brain of APP/PS1 mice in a
manner nearly identical to parallel sections stained by the plaque-
specific dye ThioflavinS or by standard immunohistochemistry
with the same antibody. The results imply that the 4G8 antibody
was specifically targeted to the amyloid plaques via K16ApoE-
mediated delivery. Similar results were also obtained with another
antibody (IgG4.1) known to label amyloid plaques (Figure S4)
[26]. Collectively, these results show that an antibody delivered in
the brain via K16ApoE can be targeted to neurons. In a separate
experiment, the 4G8 IgG delivered via K16ApoE in a normal
Figure 2. K16ApoE-mediated delivery of beta-galactosidase in
various organs. Slides of 25 micron thickness were made with tissues
from different organs and stained for beta-galactosidase activity after
delivery. Left panel – no K16ApoE; right panel – with K16ApoE.
doi:10.1371/journal.pone.0028881.g002
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experiment, a monoclonal antibody L227, not specific to the
amyloid plaques [34], did not appear to label any amyloid plaques
when delivered to the brain of an AD-mouse via K16ApoE (Figure
S6).
The peptide transporter K16ApoE does not impair the
BBB
For therapeutic and/or diagnostic use, a transporter that
efficiently carries a protein in the brain should not impair the
integrity of the BBB. To evaluate integrity of the BBB upon
K16ApoE-mediated delivery, we first injected the peptide
intravenously, then injected beta-galactosidase at different time
intervals. The control mice received the enzyme mixed with the
peptide. Mice were perfused and sacrificed 6 h after injection of
beta-galactosidase, brain slices were prepared and subjected to
beta-galactosidase staining. Results presented in Figure 5 show
successively weaker beta-galactosidase activity in the brains of
mice receiving beta-galactosidase at 1, 5 and 10 min after injection
of K16ApoE and no visible staining thereafter. Our interpretation
of these results is that most of the injected K16ApoE binds with
proteins and cells in the circulation. This intravascular binding is
virtually complete within 10 min, after which no free K16ApoE
remains in the circulation. Free K16ApoE that remains at early
time points becomes bound with beta-galactosidase and carries the
enzyme in the brain. The peptide by itself and/or being bound
with blood proteins/cells does not seem to affect the BBB since no
beta-galactosidase enzyme activity is seen in the brain from
10 min to 6 h. An alternative explanation is that the transporter
does compromise the BBB, but the damage is spontaneously
repaired in a short time (within ,10 mins). We note that animals
receiving iv injection of K16ApoE alone or mixed with beta-
galactosidase, IgG or IgM showed no visually detectable
behavioral or physiological impairment for up to 24 h (longest
time observed). It remains to be seen if K16ApoE compromises the
integrity of the BBB in the context of passage of small molecules.
Discussion
We have demonstrated the ability of a synthetic peptide,
K16ApoE, as a transporter of target proteins in the brain
employing a simple ‘mix-and-inject’ approach. The most notable
aspect of the transporter, unlike current methods, is that it does not
need to be chemically linked to a protein ‘load’ to be transported
across the BBB. Thus, K16ApoE may be regarded as a universal
protein delivery agent for the brain. Transport of proteins to the
brain by K16ApoE was evaluated by employing three different
strategies (enzyme activity, radiologic imaging and immunostain-
ing), and by delivering three different proteins of diverse molecular
weight. As far as we know, this is the first report of a delivery
reagent, targeting uptake of a protein by the brain that does not
require any chemical linking between the transporter and the
protein. We have delivered functional beta-galactosidase to the
brains of .100 mice with this peptide transporter, and successful
delivery have been observed in every instance.
Figure 3. Evaluation of K16ApoE-mediated delivery of IgG (A) and IgM (B) in brain by microSPECT. Imaging was done at 1 h interval up
to six hours, after which cardiac perfusion was performed, and final imaging carried out 30 min after perfusion. Blue bars – delivery with K16ApoE; red
bars – delivery without K16ApoE. The upward arrows at time 6 h indicate time when cardiac perfusion was performed. Right panel – microSPECT
images of mice head after perfusion after delivery of radiolabeled IgG and IgM. B – brain; S – salivary gland; T – thyroid.
doi:10.1371/journal.pone.0028881.g003
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the brain must be able to recognize and bind with an intracranial
target molecule and remain biologically functional. By delivering
anti-amyloid antibodies in the brains of AD mice through
K16ApoE, and observing that the delivered antibodies label the
amyloid plaques in a manner almost indistinguishable to
identifying the plaques through standard immunohistochemistry
coupled with the demonstration that the delivered molecules
retains biological activity (results of the beta-galactosidase based
experiments) raises the possibility that K16ApoE has potential for
clinical applications. It is intriguing to note that despite
availability of methods for delivering proteins across the BBB
for nearly two decades, successful translational application of
these methods, to date, remains challenging. The limitation
imposed by the requirement of chemically conjugating a target
protein to a transporter entity may underlie such a scenario.
Since our peptide transporter specifically abolishes the require-
ment of chemical linkage between a transporter and a protein
load, we believe our peptide transporter will allow rapid pre-
clinical evaluation of numerous potential protein-drugs currently
in the pipeline.
We have not, so far, specifically addressed quantifying the
fraction of injected dose of a protein that ultimately is transported
to the brain parenchyma through K16ApoE. We speculate that to
achieve such quantification, the contribution of the vessel-bound
target protein that remains even after perfusion needs to be
completely eliminated. Results presented in Figure 3 indicate that
,1.5% of the immunoglobulins injected entered the brain.
Further experiments are in progress along this line. Whether
delivery of this magnitude will have any clinical significance
remains to be seen, however, since we observe intense beta-
galactosidase staining in virtually all areas of the brain, and that
most or all beta-amyloid plaques in the brain become labeled with
antibodies delivered in the AD mice through the transporter, we
remain hopeful that the transporter will have reasonable clinical
relevance.
In addition to providing evidence for a simple reagent as
transporter of proteins across the BBB, our approach also
illustrates a general strategy to develop similar reagents based
upon ligand-receptor systems on the BBB. Conceivably, varying
the length and composition of the polybasic amino acid moiety
coupled with varying the length of the ApoE moiety might yield
even better transporter than K16ApoE. Discovery of BBB-specific
ligand-receptor system, if any, that functions like the ApoE-LDLR,
should provide avenues to deliver therapeutic proteins in the brain
without affecting other organs. It remains to be seen if proteins
delivered in this manner will have therapeutic effects against brain-
associated disorders.
Table 1. Evaluation of peptide transporter-mediated uptake
of IgG and IgM*.
Protein delivered Time (hr) Fold-Change** P-Value
IgG 0 0.96 0.3523
1 1.53 ,0.0001
21 . 7 ,0.0001
3 1.79 ,0.0001
4 1.91 ,0.0001
5 2.08 ,0.0001
6 1.83 ,0.0001
6.5 4.89 ,0.0001
IgM 0 1.01 0.8617
1 1.37 0.0004
2 1.56 0.0013
3 1.76 0.0005
4 2.07 0.0017
5 2.09 0.0021
6 2.24 0.0008
6.5 3.94 0.0009
*Mice were injected with the radiolabeled immunoglobulin with or without
prior mixing with the peptide transporter. MicroSPECT imaging was done from
0 to 6 h without perfusion. Cardiac perfusion was carried out at 6 h post-
injection and final imaging was done 30 min later. Six mice were used in each
group.
**Fold-Change refers to uptake with the transporter divided by uptake without
the transporter.
doi:10.1371/journal.pone.0028881.t001
Figure 4. Labeling of amyloid plaques with a plaque-specific
antibody (4G8) delivered via K16ApoE in brains of mice
models of Alzheimer’s disease (AD). Two mice with AD were
used: one represented by A, C and E are adjacent brain sections from
one mouse, while adjacent sections from the other mouse are
represented by B, D and F. A, B – thioflavine S staining; C, D –
immunostaining to identify plaques using the 4G8 as the primary
antibody, and an anti-mouse antibody as the secondary antibody; E, F –
immunostaining using the secondary antibody only. The 4G8 IgG was
injected in the first mouse (left panel) without K16ApoE, while the
second mouse (right panel) received injection of the IgG mixed with
K16ApoE. Numbers 1–5 represents approximately corresponding
plaques. Scale bar – 100 micrometer.
doi:10.1371/journal.pone.0028881.g004
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Figure S1 Time course for beta-galactosidase delivery
in mouse brain with K16ApoE. In each animal, one nanomole
of beta-galactosidase was mixed with 70 nanomoles of K16ApoE
and injected intravenously. Brain slices were prepared for staining
for beta-galactosidase activity at indicated time points. A- Beta-
galactosidase, no K16ApoE, 6 h. B- Beta-galactosidase+ K16ApoE,
1 h. C- Beta-galactosidase+ K16ApoE, 2 h. D- Beta-galactosidase+
K16ApoE, 6 h. E- Beta-galactosidase+ K16ApoE, 10 h.
(TIFF)
Figure S2 microSPECT images of accumulation of
125IgG and
125IgM in various organs. In such experiments,
spleen and liver could not be adequately separated. Consequently,
these two organs were collected as one entity. Imaging (and,
therefore, counting of radioactivity) was done at 1 h interval up to
6 h, at which time cardiac perfusion was done. A final imaging was
done 30 min after perfusion. Left panel –IgG; right panel –IgM.
Blue bars – with K16ApoE; red bars – without K16ApoE. Arrows
indicate time at which cardiac perfusion was done.
(TIFF)
Figure S3 Labeling of amyloid plaques with 4G8
antibody delivered with and without K16ApoE in mice
models of Alzheimer’s disease. Two mice with AD were
used: A, C and E represent adjacent brain sections from one
mouse, whereas B, D and F represent adjacent brain sections from
another mouse. A, B – thioflavine S staining; C, D –
immunostaining to identify plaques using the 4G8 as the primary
antibody, and an anti-mouse antibody as the secondary antibody;
E, F – immunostaining using the secondary antibody only. The
4G8 IgG was injected in the first mouse (left panel) without
K16ApoE, while the second mouse (right panel) received injection
of the IgG mixed with K16ApoE.
(TIFF)
Figure 5. Evaluation of the integrity of the BBB after injection of K16ApoE. Separate mouse (represented by A through G) all received an
injection of K16ApoE, followed by injection of beta-galactosidase at indicated times. Brain slices were made 6 h after beta-galactosidase injection and
proceeded with staining for activity of the enzyme. A – Beta-galactosidase was injected 1 min after K16ApoE injection. B – Beta-galactosidase was
injected 5 min after K16ApoE injection. C – Beta-galactosidase was injected 10 min after K16ApoE injection. D – Beta-galactosidase was injected
30 min after K16ApoE injection. E – Beta-galactosidase was injected 1 h after K16ApoE injection. F – Beta-galactosidase was injected 2 h after
K16ApoE injection. G – Beta-galactosidase was injected 4 h after K16ApoE injection. H- positive control (beta-galactosidase mixed with K16ApoE was
injected, brain slices were made 4 h after the injection and stained for enzyme activity.
doi:10.1371/journal.pone.0028881.g005
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28881Figure S4 Labeling of amyloid plaques with IgG4.1
delivered with and without K16ApoE in mice models of
Alzheimer’s disease. Two mice with AD were used: A, C and
E represent adjacent brain sections from one mice, whereas B, D
and F represent adjacent brain sections from the second mouse. A,
B – thioflavine S staining; C, D – immunostaining to identify
plaques using the IgG4.1 as the primary antibody, and an anti-
mouse antibody as the secondary antibody; E, F – immunostaining
using the secondary antibody only. The IgG4.1 was injected in the
first mouse (left panel) without K16ApoE, while the second mouse
(right panel) received injection of the IgG mixed with K16ApoE.
(TIFF)
Figure S5 Labeling of amyloid plaques with 4G8 IgG
delivered with K16ApoE in normal mouse and in a
mouse model of Alzheimer’s disease. Two mice were used
in the experiment: one normal mouse represented by A, C and E,
and one mouse with AD represented by B, D and F. A, C and E
represent adjacent brain sections from the normal mouse, whereas
B, D and F represent adjacent brain sections from the AD mouse.
A, B – thioflavine S staining; C, D – immunostaining to identify
plaques using the 4G8 IgG as the primary antibody, and an anti-
mouse antibody as the secondary antibody; E, F – immunostaining
using the secondary antibody only. The 4G8 IgG was injected in
the two mice mixed with K16ApoE. Numbers indicate corre-
sponding plaques. Scale bar – 100 micrometer.
(TIFF)
Figure S6 Evaluation of specificity of labeling of
amyloid plaques with a plaque-specific antibody
IgG4.1 (right panel) and a non-specific control (isotype)
antibody L227 (left panel) delivered via K16ApoE in the
brains of mice models of Alzheimer’s disease (AD). Two
mice with AD were used: one represented by A and C, which are
adjacent brain sections from one mouse, while adjacent sections
from the other mouse are represented by B and D. A,B -
thioflavine S staining; C,D - immunostaining using the secondary
antibody only. The L227 IgG was injected in the first mouse (left
panel) mixed with K16ApoE, while the second mouse (right panel)
received injection of the IgG4.1 mixed with K16ApoE. Numerous
plaques were labeled by IgG4.1 (panel D) but none were
apparently labeled by the L227 antibody (panel C). Numbers
represent approximately corresponding plaques. Scale bar – 100
micrometer.
(TIF)
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